Sarepta licenses, options Duchenne's gene therapy programs from Nationwide Children's; later exercised
Sarepta Therapeutics Inc. signed concurrent agreements to research and develop two preclinical Duchenne muscular dystrophy (DMD) gene therapy candidates in collaboration with Nationwide Children's Hospital, exclusively licensing the institution's Galgt2 (beta1, 4-N- acetylgalactosamine galactosyltransferase) program and also securing an exclusive option for Nationwide's microdystrophin program.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.